PMGC Holdings Inc. Following Skincare Subsidiary Sale, Embarks on Bold Growth Strategy
PMGC Holdings Inc. Following Skincare Subsidiary Sale, Embarks on Bold Growth Strategy
Divestiture Highlights Strategic Plans on Potential High-Impact Acquisitions
剝離高亮戰略計劃以潛在高影響力收購
Strategic Divestment Reduces Cash Burn and Enhances Operational Efficiency
戰略性剝離減少資金消耗並提升運營效率
NEWPORT BEACH, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the "Company" or "PMGC") (Nasdaq: ELAB) today announced its commitment to accelerating shareholder value creation and market leadership following the sale of its skincare subsidiary, Elevai Skincare. This strategic divestiture marks a significant milestone in PMGC's journey as a diversified holding company.
加利福尼亞州新港海灘,2025年1月2日(全球新聞通訊)—— PMGC控股公司(前身爲Elevai Labs Inc.)(「公司」或「PMGC」)(納斯達克:ELAB)今天宣佈承諾加速股東價值創造和市場領導力,此次剝離其護膚子公司Elevai Skincare。此項戰略性剝離標誌着PMGC作爲多元化控股公司的旅程中的一個重要里程碑。
The sale was executed to maximize immediate financial benefit while securing future upside through structured royalties and milestone payments. It has notably strengthened PMGC's balance sheet, reduced operational losses, and paved the way for new opportunities that align with the company's long-term vision.
此次出售旨在最大化立即的財務收益,同時通過結構化的特許權使用費和里程碑付款確保未來的收益。這顯著增強了PMGC的資產負債表,減少了運營損失,併爲與公司長期願景相一致的新機會鋪平了道路。
Strategic Rationale: Think Bigger, Act Bold
戰略理由:思維更大,行動更果敢
The divestiture underscores PMGC's strategy to focus on acquiring transformative assets and businesses that deliver substantial growth and shareholder value. This sale frees the Company to look for bigger opportunities. Executive management's goal is not incremental improvement but exponential growth through strategic acquisitions and steadfast execution.
此次剝離強調了PMGC聚焦於收購能帶來顯著增長和股東價值的變革性資產和業務的策略。此次出售使公司能夠尋找更大的機會。執行管理層的目標不是增量改進,而是通過戰略收購和堅定執行實現指數級的增長。
Key Financial and Operational Highlights Post Sale
出售後的關鍵財務和運營亮點
- Burn Rate Reduction: By eliminating a loss-generating subsidiary, PMGC ensures a leaner and more focused operational framework.
- Strengthened Financials: PMGC will receive approximately $1.1 million in Carmell Corporation stock and retains a lucrative 5% royalty on skincare revenues over the next five years, alongside milestone payment opportunities.
-
Growth Capital: Resources will now be channeled into high-potential assets, leveraging PMGC's drive and expertise in creating shareholder value.
- 燒錢率降低:通過剝離一個虧損的子公司,PMGC確保了一個更精簡和更專注的運營框架。
- 財務狀況增強:PMGC將收到約110萬的卡梅爾公司股票,並在未來五年內保留5%的護膚收入特許權使用費,以及里程碑支付機會。
- 增長資本:資源將被引導至高潛力資產,利用PMGC在創造股東價值方面的驅動力和專業知識。
Why It Matters to Shareholders
爲何這對股東重要
This move demonstrates PMGC's agility in adapting to market opportunities and its unwavering commitment to delivering shareholder value. The sale of Elevai Skincare is a step toward creating a portfolio of assets that reflects the company's expansive vision and ambition.
這一舉動展示了PMGC在適應市場機會方面的敏捷性,以及其對提供股東價值的堅定承諾。Elevai Skincare的出售是邁向創建一個反映公司廣闊願景和雄心的資產組合的一步。
For investors, this signals a moment of transition and opportunity. As PMGC positions itself to seize larger, more impactful opportunities, shareholders can look forward to the potential for increased returns, reduced risk, and sustainable growth.
對於投資者而言,這標誌着一個過渡和機遇的時刻。隨着PMGC定位自我以抓住更大、更具影響力的機會,股東可以期待潛在的回報增加、風險降低和可持續增長。
Looking Ahead: Growth, Diversification, and Opportunity
展望未來:增長、多元化與機遇
PMGC is actively exploring accretive acquisitions and licensing opportunities in sectors poised for significant growth. The Company is focused on identifying undervalued assets and businesses that align with a vision of building a diversified and growth-oriented holding company.
PMGC正在積極探索增值收購和許可機會,專注於快速增長行業。公司致力於識別與建立多元化和以增長爲導向的控股公司願景相一致的被低估資產和業務。
PMGC Holdings Inc. will continue to expand its company portfolio with a focus on innovation, growth, and shareholder value creation. Current subsidiaries include:
PMGC控股公司將繼續擴大其公司投資組合,重點關注創新、增長和股東價值創造。當前子公司包括:
Elevai Biosciences: a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Our lead asset, EL-22, is leveraging an engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit .
Elevai生物科學:一傢具專注於開發和收購尖端美容藥物的生物製藥公司。我們的主要資產EL-22採用工程化益生菌的方法來解決減肥治療過程中的肥胖問題,旨在減重時保護肌肉,包括GLP-1受體激動劑。更多信息請訪問。
Elevai Research: a research and development subsidiary, currently utilizing Canadian research grants and partnering with leading Canadian Universities to push the boundaries of innovation
Elevai研究:一家研究與開發子公司,目前正在利用加拿大的研究補助金,並與加拿大領先的高校合作,推動創新的邊界。
PMGC Capital LLC: a multi-strategy investment vehicle engaging in investing, lending, and seeking diversified investment opportunities across various markets.
PMGC Capital LLC:一個多策略投資工具,專注於投資、借貸,並在各個市場尋找多樣化投資機會。
The current subsidiaries and pending opportunities underscore PMGC's focus on thinking bigger and its drive to build a growth-oriented portfolio.
當前的子公司和待處理機會突顯了PMGC的遠大目標和推動建立以增長爲導向的投資組合的決心。
About PMGC Holdings Inc.
關於PMGC控股公司。
PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. Currently, our portfolio consists of three wholly owned subsidiaries: Elevai Biosciences Inc., Elevai Research Inc., and PMGC Capital LLC. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit .
PMGC控股公司是一家多元化控股公司,通過戰略收購、投資和在各個行業的開發來管理和擴大其投資組合。目前,我們的投資組合包含三家全資子公司:Elevai Biosciences Inc.、Elevai Research Inc.和PMGC Capital LLC。我們致力於探索多個行業的機會,以最大化增長和價值。有關更多信息,請訪問。
Forward-Looking Statements
前瞻性聲明
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "believes," "expects," "plans," "potential," "would" and "future" or similar expressions such as "look forward" are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC Holdings' filings with the United States Securities and Exchange Commission ("SEC"), including the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
本新聞稿中關於非歷史事實事項的聲明屬於《1995年私人證券訴訟改革法案》所指的「前瞻性聲明」。諸如「相信」、「預計」、「計劃」、「潛力」、「將會」和「未來」等詞語或類似表達例如「期待」的短語旨在識別前瞻性聲明。前瞻性聲明在本新聞稿發出之日作出,並非歷史事實或未來業績的保證。相反,它們僅基於我們當前對業務未來、未來計劃和策略、預測、預期事件和趨勢、經濟、監管機構活動和未來法規及其他未來條件的信念、期望和假設。由於前瞻性聲明涉及未來,因此它們受到固有的不確定性、風險和難以預測的環境變化的影響,其中許多超出了我們的控制範圍。儘管公司相信這些前瞻性聲明中表達的期望是合理的,但不能保證這些期望會是正確的,公司提醒投資者,實際結果可能與預期結果有重大差異。因此,您不應依賴於這些前瞻性聲明。這些及其他風險在PMGC Holdings向美國證券交易委員會(「SEC」)提交的文件中進行了更詳細的描述,包括公司截至2023年12月31日的年度報告中「風險因素」部分,該報告於2024年3月29日向SEC提交,以及其隨後向SEC提交或提供的其他文件。我們鼓勵投資者和證券持有人在SEC網站www.sec.gov上免費閱讀這些文件。所有在本新聞稿中的前瞻性聲明僅在作出時有效。除法律要求的範圍外,公司沒有義務更新這些聲明,以反映在作出聲明後發生的事件或存在的情況。
IR Contact:
IR@pmgcholdings.com
投資者關係聯繫人:
IR@pmgcholdings.com